Clinical trialPhase 1Recruiting

A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous ABBV-253 Moves Through the Body in Adult Participants With Advanced Solid Tumors

A Phase 1 First-in-human, Open-label Study Evaluating Safety, Pharmacokinetics, and Efficacy of ABBV-253 in Adult Subjects With Advanced Solid Tumors

NCT07807956 ↗ ClinicalTrials.gov, retrieved 4 November 2026

Outcome: Ongoing
Phase: Phase 1
Status: Recruiting
Study type: Interventional
Start: 14 September 2026
Expected end: December 2029
Enrollment: 130 participants
Sites: 3
Primary outcomes: Number of Participants With Adverse Events; Number of Participants with Abnormal Change from Baseline in Clinical Laboratory Test Results; Number of Participants with Abnormal Change From Baseline in Vital Sign Measurements; Number of Participants with Change from Baseline in Electrocardiogram (ECG); Objective Response (OR)
Sponsor: Industry
Results posted: No
Last update: 16 October 2026

These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess. Only its metadata is loaded so far, so most questions will be declined.

Try